Technologies

In our recent publication we identified a group of  bladder cancer-specific ncRNA, called T-UCRs that are the most up-regulated in bladder cancer patient samples compared with normal bladder urothelium.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.

This invention comprises an interrogation and readout differential method for chemical sensors based on Surface Plasmon Resonances (SPR). The integration of the SPR sensing unit (chip or other), as intermediate reflecting element of a Fabry-Perot (FP) optical resonator, is the starting point for the application of this method.

Portable robotic device for bilateral neuromotor rehabilitation. An appropriate mechanical structure and a series of interchangeable accessories suitably designed allow the execution of various motor gestures of the upper limbs, involving different articulations and muscles. The possibility of being used with both limbs contributes to the recovery of motor coordination and facilitates the mechanism of brain plasticity. Some rotary axes the device is equipped with are motorized and sensorized.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

NANOINCICLO is a technology based on the use of nanostructured cyclodextrins (CDs) for the targeted delivery of drugs such as anticancer drugs, photodynamic drugs, anti-inflammatories, antivirals, antibacterials, nutraceuticals and metals with therapeutic and diagnostic properties. Successful CDs for the proposed technology are FDA-approved or in advanced pre-clinical investigational stage and include natural and functionalized, polymeric, and amphiphilic monomeric CDs.

The development of new materials with near-infrared emission (NIR, 700 – 1000 nm) represent an important target in the technological progress of innovative active components for OLED devices (including flexible ones), surveillance systems, autonomous driving, night vision sensors, fiber optic telecommunications and medical systems. In all these fields it still lacks a commercial NIR-OLED technology.

Therapeutic strategies targeting cell cycle in cancer have in general failed in the clinic since the drugs have lacked the therapeutic index required to achieve a robust response against cancer cells with little or no cytotoxic effect on normal cells. NEK6 kinase, which is implicated in cell cycle control, has recently emerged as an attractive target for the development of novel anticancer drugs with enhanced therapeutic index.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

Filamentous bacteriophages for size, in vivo biodistribution and easiness of engineering, are considered as natural nanoparticles. The developed technology allows the construction of bio-nanoparticles based on filamentous bacteriophages delivering proteic antigens and immunomodulating lipids. Thanks to the high content of hydrophobic residues, phage capsid proteins have high binding affinity to lipids, allowing the conjugation of immunostimulating lipids.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

The platform allows acquisition of data from commercial and custom sensors. By now, the system has been embedded in a wearable wristband where elastomeric based strain gauge have been integrated to detect fine hand/wrist/arm movements. The platform integrates inertial sensors (accelerometers, gyroscopes) to acquire more details about the subject movements. A sensor-fusion algorithm enables advanced movement recognition (gesture, 3D orientation). A machine-learning algorithm is in development to increase the performance of the platform.

The environment as well as the food production provide a number of both natural and synthetic compounds whose effects on human being as an organism have not yet been determined nor investigated.